Regenerative Patch Technologies

Executive Summary

Regenerative Patch Technologies (RPT) is a clinical-stage biotechnology company developing a novel cell-based implant, CPCB-RPE1, for the treatment of geographic atrophy (GA) secondary to advanced dry age-related macular degeneration (AMD). The implant consists of a bioengineered patch of stem cell-derived retinal pigmented epithelial (RPE) cells designed to replace the RPE layer lost in GA, thereby preserving photoreceptors and vision. RPT is currently in Phase 2 clinical trials, building on promising Phase 1/2a data that demonstrated safety and preliminary efficacy, including slowing of disease progression. GA represents a large and growing unmet need, affecting millions worldwide with no approved treatments that stop or reverse vision loss. RPT's approach is one of the most advanced cell therapies in the ophthalmology space, and the company is well-positioned with strong preclinical and clinical datasets. RPT's primary near-term catalyst is the completion and data readout from its ongoing Phase 2 trial, which is expected in late 2026 or early 2027. Positive results could support progression to a pivotal Phase 3 study and potentially accelerate regulatory discussions. The company is also likely to seek FDA recognition such as fast track or breakthrough therapy designation to expedite development. Additionally, RPT may attract strategic partnerships or licensing interest from larger ophthalmology or cell therapy companies, given the high unmet need and competitive landscape. With a seasoned management team and a unique platform, RPT represents a compelling opportunity in regenerative medicine for retinal diseases.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Interim Efficacy and Safety Data Readout50% success
• Q3 2026FDA Fast Track or Breakthrough Therapy Designation70% success
• H1 2027Strategic Partnership or Licensing Agreement40% success